Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 SGI-110 versus treatment choice in untreated AML patients unfit for intensive induction
NL-OMON45193Phase 3Active, not recruiting
- Sponsor
- Astex Pharmaceuticals
- Start
- Apr 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of guadecitabine, cytarabine, decitabine and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by Astex Pharmaceuticals. Primary endpoints: Complete response rate and Overall survival. Started Apr 2016; status: active, not recruiting.
02
Drugs
guadecitabinecytarabinedecitabineazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON45193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45193.